1. Indications:

Imakin (Imatinib INN) 100 mg is indicated for the treatment of:

• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
• Ph+ CML in accelerated phase or blast crisis.
• Unresectable or metastatic gastrointestinal stromal tumors (GISTs).

2. Pharmacology:

Imakin (Imatinib INN) 100 mg exerts its pharmacological effects by selectively inhibiting the activity of specific tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-R. Dysregulation of these kinases is characteristic of conditions such as CML and GISTs. By blocking their activity, Imakin impedes cancer cell proliferation, promotes apoptosis (cell death), and inhibits tumor angiogenesis, ultimately leading to tumor regression.

3. Dosage and Administration:

The recommended dosage of Imakin (Imatinib INN) 100 mg may vary depending on the specific cancer being treated and individual patient factors. Typically, the prescribed dose is 100 mg taken orally once daily, preferably with a meal and a full glass of water. Treatment duration is determined based on the patient’s response and tolerance to the medication.

4. Interaction:

Imakin (Imatinib INN) 100 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Concurrent use with drugs affecting CYP3A4 metabolism may impact Imakin’s plasma concentration.
• Acid-reducing agents: Co-administration with proton pump inhibitors (PPIs) or H2-receptor antagonists may reduce Imakin absorption, potentially affecting its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to prevent potential interactions.

5. Side Effects:

Common side effects associated with Imakin (Imatinib INN) 100 mg may include:

• Nausea
• Fatigue
• Edema (fluid retention)
• Muscle cramps
• Skin rash
• Diarrhea

Patients should promptly report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before initiating treatment with Imakin (Imatinib INN) 100 mg, patients should be mindful of the following precautions:

• Imakin may cause myelosuppression, characterized by reduced blood cell counts. Regular blood count monitoring is essential during therapy.
• Hepatotoxicity, including liver function abnormalities, has been reported with Imakin. Liver function tests should be conducted before treatment initiation and periodically thereafter.
• Imakin may prolong the QT interval, increasing the risk of arrhythmias. Therefore, regular electrocardiogram (ECG) monitoring is advisable, particularly in patients with existing cardiac conditions.

7. Overdose Effects:

In the event of an overdose with Imakin (Imatinib INN) 100 mg, supportive care measures should be promptly initiated. Symptomatic treatment may be administered as required. As there is no specific antidote for Imakin overdose, patients suspected of overdose should seek immediate medical attention.